This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.

The tool connects to electrodes implanted in people with epilepsy or other brain conditions and can monitor and regulate neurons during everyday activities.

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

Brain cell clusters serve as drug screens and reveal connectivity differences for autism-linked conditions, two new models show.

The temporary easing of traits that a minority of autistic children are reported to show during or after a fever may stem from a rise in body temperature.

Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.

This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.

The drug quells seizures in children with Dravet syndrome or Lennox-Gastaut syndrome.

Prenatal exposure to topiramate increases a child’s autism odds, according to the study that prompted the inquiry, but experts caution that pregnant people with epilepsy have few other options for controlling seizures.